- Price is above Fair Value, showing premium demand versus the model.
ALMR
NASDAQ
Week ended 24 Jul 2026
Weekly Investor Report
Alamar Biosciences, Inc. Common Stock · Healthcare · Medical Devices
Latest close
25.88 USD
-0.3%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is - below the Trend Line and sits at 66.5% of its 52-week range. The latest completed week returned -0.3%, after a -3.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal; earnings are due in 7d.
Setup score
33
out of 100
Latest Close
25.88 USD
24 Jul 2026
1W Return
-0.3%
latest completed week
4W Return
-3.0%
short-term follow-through
12W Return
0.3%
quarterly tape
Trend Breadth
0.0%
0 of 15 weeks active
Volume Ratio
0.7x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Activity pressure is negative, which weakens the current setup.
- Activity pressure is weak, so confirmation is not yet broad enough.
- 6 reversal markers appear in the recent smart-money tape.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-0.3%
Latest completed week; four-week move -3.0%.
Indicator stack
0/50
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
52/100
41 relevant articles in the latest sentiment read.
Event risk
7d
Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is - below the Trend Line and sits at 66.5% of its 52-week range. The latest completed week returned -0.3%, after a -3.0% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1412-week average 0.03
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.14Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers66 reversal markers
No recent accumulation markers. 6 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -3.0% over four weeks, 0.3% over 12 weeks, and - over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.00Latest activity-pressure read.
Pressure change-Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Dec 2025
Field coverage 64%
Model confidence 61%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength74/100Blend of value, momentum, and quality. Underlying universe rank 27; rank 1 is best.
Value62/100Relative valuation strength. Underlying universe rank 39; rank 1 is best.
Quality60/100Profitability and accounting quality. Underlying universe rank 41; rank 1 is best.
Momentum62/100Medium-term price momentum. Underlying universe rank 39; rank 1 is best.
Growth62/100Revenue and earnings growth. Underlying universe rank 39; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 24.2x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -2.3% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 56.2% Gross profit retained from each unit of revenue.
- Operating margin
- -38.7% Operating profit retained from revenue.
- Free-cash-flow margin
- -63.6% Free cash flow generated from revenue.
- Return on invested capital
- -22.0% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 195.2% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 4/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -0.1% Net share repurchases relative to market value.
- Shareholder yield
- -0.1% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -11.1x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment52/100
Weighted news tone is neutral across 41 relevant articles.
3 positive · 38 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings7dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-12.1%Distance below the 52-week high.
13-week volatility8.3%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
17 Apr
15 May
12 Jun
10 Jul
24 Jul
Weeks higher7 of 147 weeks finished lower.
Best week+21.4%Week of 26 Jun.
Worst week-10.1%Week of 15 May.
Latest week-0.3%Week of 24 Jul.
Shape of recent returns
Strong gains4
Modest gains3
Flat weeks0
Modest losses3
Sharp losses4
Recent vol8.3%13-week weekly-return volatility.
Base vol8.6%52-week weekly-return volatility.
Up/down split7/7Count of positive and negative weeks in the 52-week window.
Average skew8.2% / -5.1%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average1.3%
Trend breadth51.0%
Trend51.0%active weekly trend signals
MD75.0%positive activity pressure
RS48.0%positive relative leadership
Four-week leaders
IndustryUS Medical Devices
4-week rank50 / 100
Group average-3.4%
Trend breadth34.0%
Trend34.0%active weekly trend signals
MD65.0%positive activity pressure
RS20.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape30/100
Trend, activity pressure, participation, and risk combine to a 30/100 tape read.
Indicator analysis3/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.14; 6 reversal markers Factors64/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 71; Small Cap Core rank 47 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment52/100Weighted news tone is neutral across 41 relevant articles.
ALMR|Alamar Biosciences Ord Shs|Price:24.400|Chg%:-1.480 Insiders50/100No recent insider transaction evidence is stored.
Earnings7dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 24 Jul 2026 | 25.88 USD | -0.3% | - | 23.73 USD | 0.00 | - | 977.2K | Off |
| 17 Jul 2026 | 25.95 USD | -8.7% | - | 23.58 USD | 0.00 | - | 1.5M | Off |
| 10 Jul 2026 | 28.42 USD | 9.6% | - | 23.40 USD | 0.00 | - | 1.0M | Off |
| 3 Jul 2026 | 25.94 USD | -2.7% | - | 22.98 USD | 0.00 | - | 1.9M | Off |
| 26 Jun 2026 | 26.67 USD | 21.4% | - | 22.71 USD | 0.00 | - | 3.4M | Off |
| 19 Jun 2026 | 21.96 USD | -0.2% | - | 22.32 USD | 0.00 | - | 1.6M | Off |
| 12 Jun 2026 | 22.00 USD | 7.1% | - | 22.35 USD | 0.00 | - | 902.0K | Off |
| 5 Jun 2026 | 20.54 USD | 0.5% | - | 22.40 USD | 0.00 | - | 752.3K | Off |
| 29 May 2026 | 20.44 USD | 1.9% | - | 22.66 USD | 0.00 | - | 1.2M | Off |
| 22 May 2026 | 20.06 USD | -6.9% | - | 23.04 USD | 0.00 | - | 1.2M | Off |
| 15 May 2026 | 21.54 USD | -10.1% | - | 23.63 USD | 0.00 | - | 998.8K | Off |
| 8 May 2026 | 23.96 USD | -7.2% | - | 24.15 USD | 0.00 | - | 1.2M | Off |
| 1 May 2026 | 25.81 USD | 3.9% | - | 24.22 USD | - | - | 1.5M | Off |
| 24 Apr 2026 | 24.84 USD | 12.9% | - | 23.42 USD | - | - | 2.8M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.